Last reviewed · How we verify
Riluzole (100 mg)
Riluzole reduces glutamate excitotoxicity by inhibiting glutamate release and blocking sodium channels in neurons.
Riluzole reduces glutamate excitotoxicity by inhibiting glutamate release and blocking sodium channels in neurons. Used for Amyotrophic lateral sclerosis (ALS), Other neurodegenerative conditions (under investigation).
At a glance
| Generic name | Riluzole (100 mg) |
|---|---|
| Also known as | Yooritek, Rilutek |
| Sponsor | AB Science |
| Drug class | Glutamate antagonist / Neuroprotective agent |
| Target | Glutamate release (presynaptic); voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Riluzole is a neuroprotective agent that works through multiple mechanisms: it inhibits the presynaptic release of glutamate, blocks inactivated sodium channels, and may enhance GABA-mediated inhibitory neurotransmission. These actions reduce excitotoxic neuronal damage caused by excessive glutamate signaling, which is implicated in neurodegenerative diseases.
Approved indications
- Amyotrophic lateral sclerosis (ALS)
- Other neurodegenerative conditions (under investigation)
Common side effects
- Asthenia / fatigue
- Nausea
- Dizziness
- Liver enzyme elevation
- Headache
Key clinical trials
- Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS) (PHASE1, PHASE2)
- PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS (PHASE2)
- Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol) (PHASE2)
- Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients (PHASE3)
- A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma (EARLY_PHASE1)
- Riluzole in Patients With Spinocerebellar Ataxia Type 7 (PHASE2, PHASE3)
- Safety and Tolerability of Anakinra in Combination With Riluzol in Amyotrophic Lateral Sclerosis (PHASE2)
- Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Riluzole (100 mg) CI brief — competitive landscape report
- Riluzole (100 mg) updates RSS · CI watch RSS
- AB Science portfolio CI